An EP4 Antagonist ONO-AE3-208 Suppresses Cell Invasion, Migration, and Metastasis of Prostate Cancer

Cell Biochemistry and Biophysics

Volumn 70, Issue 1, 2014, Pages 521-527

  Xu, Song ^a   Zhang, Zhengyu ^a   Ogawa, Osamu ^b   Yoshikawa, Takeshi ^b   Sakamoto, Hiromasa ^b   Shibasaki, Noboru ^b   Goto, Takayuki ^b   Wang, Liming ^a   Terada, Naoki ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

EP4; Metastasis; Prostate cancer

Indexed keywords

MUS MUSCULUS;

4-(4-CYANO-2-(2-(4-FLUORONAPHTHALEN-1-YL)PROPIONYLAMINO)PHENYL)BUTYRIC ACID; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; NAPHTHALENE DERIVATIVE; PROSTAGLANDIN E RECEPTOR 4;

ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; SECONDARY; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NAPHTHALENES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHENYLBUTYRATES; PROSTATIC NEOPLASMS; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906272556     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-9951-2     Document Type: Article

References (24)

1. Gronberg, H. (2003). Prostate cancer epidemiology. Lancet, 261, 859.
2. Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10.
3. Terada, N., Shimizu, Y., Kamba, T., et al. (2010). Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Research, 70, 1606.
4. Xin, X., Majumder, M., Girish, G. V., et al. (2012). Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Laboratory Investigation, 92, 1115.
5. Takita, M., Inada, M., Maruyama, T., et al. (2007). Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells. FEBS Letters, 581, 565.
6. Karavitis, J., Hix, L. M., Shi, Y. H., et al. (2012). Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLoS One, 7, e46342.
7. Xing, N. D., Ding, S. T., Saito, R., et al. (2011). A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-l-cysteine, a novel Eg5 inhibitor. Asian Journal of Andrology, 13, 236.
8. Kabashima, K., Sakata, D., Nagamachi, M., et al. (2003). Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nature Medicine, 9, 744.
9. Saito, R., Shirakawa, R., Nishiyama, H., et al. (2013). Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer. Oncogene, 32, 894.
10. Wu, T. T., Sikes, R. A., Cui, Q., et al. (1998). Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. International Journal of Cancer, 77, 887.
11. Platz, E. A., De Marzo, A. M. (2004). Epidemiology of inflammation and prostate cancer. Journal of Urology, 171, S36.
12. De Marzo, A. M., Platz, E. A., Sutcliffe, S., et al. (2007). Inflammation in prostate carcinogenesis. Nature Reviews Cancer, 7, 256.
13. Veitonmäki, T., Tammela, T. L., Auvinen, A., et al. (2013). Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. European Journal of Cancer, 49, 938.
14. Abedinpour, P., Baron, V. T., Welsh, J., et al. (2011). Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo. Prostate, 71, 813.
15. Katkoori, V. R., Manne, K., Vital-Reyes, V. S., et al. (2013). Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Biotechnic and Histochemistry, 88, 38.
16. Ray, W. A., Stein, C. M., Daugherty, J. R., et al. (2002). COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet, 360, 1071.
17. Ma, X., Kundu, N., Rifat, S., Walser, T., et al. (2006). Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Research, 66, 2923.
18. Mutoh, M., Watanabe, K., Kitamura, T., et al. (2002). Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Research, 62, 28.
19. Kim, J. I., Lakshmikanthan, V., Frilot, N., et al. (2010). Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Molecular Cancer Research, 8, 569.
20. Rundhaug, J. E., Simper, M. S., Surh, I., et al. (2011). The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer and Metastasis Reviews, 30, 465.
21. Wu, J., Zhang, Y., Frilot, N., et al. (2011). Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. Journal of Biological Chemistry, 286, 33954.
22. Huang, H. F., Shu, P., Murphy, T. F., et al. (2013). Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer. Molecular Cancer Research, 11, 427.
23. Kabashima, K., Sakata, D., Nagamachi, M., et al. (2003). Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nature Medicine, 9, 744.
24. Yang, L., Huang, Y., Porta, R., et al. (2006). Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Research, 66, 9665.